Condition: Graft-versus-host Disease (GVHD) · Sponsor: Incyte Corporation
The purpose of this study is to assess Tacrolimus/Methotrexate/Ruxolitinib versus Post-Transplant Cyclophosphamide/Tacrolimus/Mycophenolate Mofetil in Non-Myeloablative/Reduced Intensity Conditioning Allogeneic Peripheral Blood Stem Cell Transplantation
This description comes directly from the study's public registry record.
Incyte Corporation Call Center (US) · 1.855.463.3463 · medinfo@incyte.com
Incyte Corporation Call Center (ex-US) · +800 00027423 · eumedinfo@incyte.com
Always discuss trial participation with your own doctor first.
| Stanford Cancer Center | Palo Alto, California, United States | Recruiting |
| University of California San Francisco | San Francisco, California, United States | Recruiting |
| University of Miami | Miami, Florida, United States | Recruiting |
| Moffitt Cancer Center | Tampa, Florida, United States | Recruiting |
| Blood and Marrow Transplant Group of Georgia | Atlanta, Georgia, United States | Recruiting |
| Indiana University Cancer Center | Indianapolis, Indiana, United States | Recruiting |
| University of Kansas Hospital Authority | Kansas City, Kansas, United States | Recruiting |
| Massachusetts General Hospital | Boston, Massachusetts, United States | Recruiting |
| Dana Farber Cancer Institute | Boston, Massachusetts, United States | Recruiting |
| University of Michigan | Ann Arbor, Michigan, United States | Recruiting |
| Karmanos Cancer Institute | Detroit, Michigan, United States | Recruiting |
| Henry Ford Hospital | Detroit, Michigan, United States | Recruiting |
+ 18 more locations — full list on the registry record.
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT06615050